[go: up one dir, main page]

WO2011117322A3 - Utilisation de caféine et d'aspirine en des quantités synergiques pour améliorer les performances - Google Patents

Utilisation de caféine et d'aspirine en des quantités synergiques pour améliorer les performances Download PDF

Info

Publication number
WO2011117322A3
WO2011117322A3 PCT/EP2011/054496 EP2011054496W WO2011117322A3 WO 2011117322 A3 WO2011117322 A3 WO 2011117322A3 EP 2011054496 W EP2011054496 W EP 2011054496W WO 2011117322 A3 WO2011117322 A3 WO 2011117322A3
Authority
WO
WIPO (PCT)
Prior art keywords
caffeine
aspirin
enhanced
produce
ergogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/054496
Other languages
English (en)
Other versions
WO2011117322A2 (fr
Inventor
John Paul Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011117322A2 publication Critical patent/WO2011117322A2/fr
Publication of WO2011117322A3 publication Critical patent/WO2011117322A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de caféine et d'aspirine, l'aspirine étant utilisée en une quantité efficace pour produire un effet ergogène augmenté de la caféine lorsqu'elle est ingérée par une personne souhaitant améliorer ses performances dans une activité sportive ou souhaitant améliorer ses performances cognitives. La présente invention concerne en outre une composition comprenant de la caféine et de l'aspirine, l'aspirine étant comprise dans la composition en une quantité efficace pour produire un effet ergogène augmenté de la caféine lorsqu'elle est ingérée par une personne souhaitant augmenter ses performances cognitives ou physiques, par exemple dans une activité sportive. Par conséquent, la présente invention concerne une composition ergogène pour produire des performances cognitives améliorées ainsi que des performances physiques augmentées, par exemple dans une activité sportive, la caféine étant incluse en une quantité pour produire un effet ergogène chez des humains ; et l'aspirine étant incluse en une quantité efficace pour produire un effet synergique avec la caféine de manière à produire un effet ergogène augmenté de la caféine.
PCT/EP2011/054496 2010-03-23 2011-03-23 Utilisation de caféine et d'aspirine en des quantités synergiques pour améliorer les performances Ceased WO2011117322A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1004831.2A GB2478931B (en) 2010-03-23 2010-03-23 Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity
GB1004831.2 2010-03-23

Publications (2)

Publication Number Publication Date
WO2011117322A2 WO2011117322A2 (fr) 2011-09-29
WO2011117322A3 true WO2011117322A3 (fr) 2012-01-12

Family

ID=42228176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/054496 Ceased WO2011117322A2 (fr) 2010-03-23 2011-03-23 Utilisation de caféine et d'aspirine en des quantités synergiques pour améliorer les performances

Country Status (2)

Country Link
GB (1) GB2478931B (fr)
WO (1) WO2011117322A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003681A1 (fr) * 1984-12-26 1986-07-03 Abraham Sunshine Produit a base d'analgesiques, d'anti-inflammatoires et de decontractants musculaires transosseux
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
WO1999003475A1 (fr) * 1997-07-14 1999-01-28 Bristol-Myers Squibb Company Composition d'acetaminophene, d'aspirine, et de cafeine attenuant la douleur et les symptomes, de la migraine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1137379A (en) * 1912-12-21 1915-04-27 Alfred W Beuttell Show-case light.
CA2369515A1 (fr) * 1999-04-06 2001-03-29 Wm. Wrigley Jr. Company Formulations pharmaceutiques de gomme a macher
US20060292225A1 (en) * 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
US20080317886A1 (en) * 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003681A1 (fr) * 1984-12-26 1986-07-03 Abraham Sunshine Produit a base d'analgesiques, d'anti-inflammatoires et de decontractants musculaires transosseux
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
WO1999003475A1 (fr) * 1997-07-14 1999-01-28 Bristol-Myers Squibb Company Composition d'acetaminophene, d'aspirine, et de cafeine attenuant la douleur et les symptomes, de la migraine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.J. MEDINA: "How does Ripped Fuel work?", 12 September 2009 (2009-09-12), XP002660406, Retrieved from the Internet <URL:http://www.livestrong.com/article/32157-ripped-fuel-work/> [retrieved on 20110930] *
FERNANDEZ-DUENAS ET AL: "Adjuvant effect of caffeine on acetylsalicylic acid anti-nociception: Prostaglandin E2 synthesis determination in carrageenan-induced peripheral inflammation in rat", EUROPEAN JOURNAL OF PAIN, SAUNDERS, LONDON, GB, vol. 12, no. 2, 30 November 2007 (2007-11-30), pages 157 - 163, XP022367496, ISSN: 1090-3801, DOI: 10.1016/J.EJPAIN.2007.03.485 *
GRAHAM T E: "Caffeine and exercise: metabolism, endurance and performance", SPORTS MEDICINE, ADIS PRESS, AUCKLAND, NZ, vol. 31, no. 11, 1 January 2001 (2001-01-01), pages 785 - 807, XP008084424, ISSN: 0112-1642, DOI: 10.2165/00007256-200131110-00002 *
HUDSON GEOFFREY M ET AL: "Effects of caffeine and aspirin on light resistance training performance, perceived exertion, and pain perception", JOURNAL OF STRENGTH AND CONDITIONING RESEARCH, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 22, no. 6, 1 November 2008 (2008-11-01), pages 1950 - 1957, XP008143297, ISSN: 1064-8011, DOI: 10.1519/JSC.0B013E31818219CB *
JAMES COLLIER: "Ephedrine & Ephedra, and the Associated Alkaloids and Compounds :: Part 2", 1 November 2009 (2009-11-01), XP002660405, Retrieved from the Internet <URL:http://articles.muscletalk.co.uk/article-ephedrine-ephedra-2.aspx> [retrieved on 20110927] *
RUBIN A ET AL: "A double-blind randomized study of an aspirin/caffeine combination versus acetaminophen/aspirin combination versus acetaminophen versus placebo in patients with moderate to severe post-partum pain.", THE JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 1984 LNKD- PUBMED:6519349, vol. 12, no. 6, 1984, pages 338 - 345, XP008143653, ISSN: 0300-0605 *
UTAH POISON CONTROL CENTER: "Drug Abuse in Sports", UTOX UPDATE, 1 January 2002 (2002-01-01), pages 1 - 4, XP055008570, Retrieved from the Internet <URL:http://uuhsc.utah.edu/poison/healthpros/utox/vol4_no1.pdf> [retrieved on 20110930] *

Also Published As

Publication number Publication date
GB2478931A (en) 2011-09-28
WO2011117322A2 (fr) 2011-09-29
GB2478931B (en) 2013-06-12
GB201004831D0 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
CA2900335C (fr) Analogues synthetiques d&#39;epipolythiodioxopiperazines et leurs utilisations
WO2011107462A3 (fr) Compositions de protection solaire
WO2015067715A3 (fr) Composés agonistes doubles de gip et glp-1 et procédés associés
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
WO2015010009A3 (fr) Compositions et méthodes comprenant un variant d&#39;enzyme lipolytique
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
WO2009089494A3 (fr) Compositions pharmaceutiques
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l&#39;integrita&#39; delle mucose.
WO2013175221A3 (fr) Composition
LT2739615T (lt) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanonai ir jų panaudojimas kaip vaisto
WO2013034855A3 (fr) Association de carraghénane et de c-glycoside et leurs utilisations
JP2014500291A5 (fr)
WO2011150457A3 (fr) Inhibiteurs de la prostaglandine d2 synthase hématopoïétique
WO2012093973A3 (fr) Formulations stables d&#39;acarbose
WO2014124398A3 (fr) Articles pour retenir une personne
WO2012173382A3 (fr) Composition à usage externe pour l&#39;épiderme, contenant du tanshinone ii a en tant que principe actif
WO2011139252A3 (fr) Formulations effervescentes comprenant du cefdinir
WO2012065028A3 (fr) Tétracyclines substituées
GB201020119D0 (en) Pharamaceutical and other compositions, e.g. for the skin, comprising emulsifying ointment and water
WO2011117322A3 (fr) Utilisation de caféine et d&#39;aspirine en des quantités synergiques pour améliorer les performances
NZ613887A (en) Antimicrobial activity enhancing agent
WO2011018477A3 (fr) Carnosol pour les soins capillaires et cutanés
WO2013012309A3 (fr) Préparation externe pour la peau
曾勇 Journal of UESTC (Social Sciences Edition) Jun. 2009, Vol. 11, No. 3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11714714

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11714714

Country of ref document: EP

Kind code of ref document: A2